Although BOADICEA includes rare pathogenic variants in moderate- and high-risk BC susceptibility genes (i.e., BRCA1, BRCA2, PALB2, ATM and CHEK2, BARD1, RAD51C, RAD51D), and PRS-313, it does not incorporate information on the systemic treatment of the primary BC, which are important predictors of CBC risk [56]. This evidence concerns the gene BARD1 and breast cancer.